Key Highlights

  • Agios Pharmaceuticals (NASDAQ:AGIO) said the FDA extended the review goal date for mitapivat in sickle cell disease by three months, from November 1, 2026 to February 1, 2027, after a major amendment.
  • The FDA asked on October 9 whether a risk evaluation and mitigation strategy is needed; the company replied on October 19 with about nine months of updated safety data, classified a major amendment on October 28.
  • In the 207-patient RISE UP phase 3 trial, 40.6 percent of mitapivat patients had a hemoglobin response versus 2.9 percent on placebo, but the annualized pain crisis rate of 2.62 versus 3.05 was not statistically significant.
  • Shares of Agios (NASDAQ:AGIO) fell roughly 18 percent on October 30, 2026, and the company held USD 964.8 million of cash at June 30, 2026.

A Three Month Delay on a Safety Question

Agios Pharmaceuticals (NASDAQ:AGIO) announced the extension as published reports dated October 30, 2026 described it. The sequence began on October 9, when the FDA asked for information to decide whether mitapivat needs a REMS, a risk evaluation and mitigation strategy, in sickle cell disease. Agios responded on October 19 with about nine months of open-label extension data from its phase 2 and phase 3 RISE UP trials. On October 28 the FDA classified that response as a major amendment, which allows a review to be extended by three months. The goal date moved from November 1, 2026 to February 1, 2027.

Why the Liver Question Travels From Thalassemia

The REMS question traces to thalassemia. In those trials, 5 of 301 patients had liver injury, 2 of them serious. Mitapivat has been sold for thalassemia under the Brand AQVESME since late January, only under a REMS, according to published coverage. Agios reports no sickle cell cases of hepatocellular injury resembling the pattern and severity seen in thalassemia, and says labeling discussions, including possible REMS elements, are ongoing. Chief executive Brian Goff said the company is launch-ready. Sickle cell disease affects about 100,000 people in the United States, and mitapivat net Revenue was USD 44.7 million in the second quarter, up from USD 12.5 million. Agios (NASDAQ:AGIO) is therefore waiting on label terms, not only approval.

Trial Data, Risks and What to Watch

RISE UP randomized 207 patients aged 16 and older, 138 to mitapivat and 69 to placebo, for 52 weeks. The hemoglobin endpoint was met, 40.6 percent versus 2.9 percent, but the pain crisis endpoint was not statistically significant. Transfusion was needed in 23.9 percent versus 40.6 percent of patients. Coverage notes that 2027 revenue estimates assumed a November launch and may need to come down. Novo Nordisk (NYSE:NVO) reported that its etavopivat cut pain crises by 27 percent in a phase 3 trial. Agios (NASDAQ:AGIO) reports third quarter results in early November, with the date unconfirmed. This is not a forecast.

Where Things Stand

The delay stems from a safety review, not a rejection: the FDA wants clarity on whether mitapivat in sickle cell disease needs a REMS, and Agios (NASDAQ:AGIO) must wait until February 1, 2027. The trial results are mixed, with a clear hemoglobin benefit and a missed pain crisis endpoint. The balance of evidence is that approval remains possible but the launch timing and label are less certain. The next catalysts are the third quarter report in early November and any label discussions ahead of the new date.